We are live on ! Find out more
SPRO icon

Spero Therapeutics
SPRO

61 hedge funds and large institutions have $122M invested in Spero Therapeutics in 2019 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 26 increasing their positions, 10 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 3

160% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 10

11% more funds holding

Funds holding: 55 → 61 (+6)

6.94% more ownership

Funds ownership: 53.81% → 60.74% (+6.9%)

3% more capital invested

Capital invested by funds: $119M → $122M (+$3.78M)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $1K

Holders
61
Holders Change
+6
Holders Change %
+10.91%
% of All Funds
1.32%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
9
Increased
26
Reduced
10
Closed
3
Calls
–
Puts
$1K
Net Calls
-$1K
Net Calls Change
-$1K

Top Buyers

1
BI
BVF Inc
California
+$5.77M
2
NHAS
Novo Holdings A/S
Denmark
+$5.61M
3
BlackRock
BlackRock
New York
+$2.84M
4
Renaissance Technologies
Renaissance Technologies
New York
+$1.22M
5
ACM
Aquilo Capital Management
California
+$1.2M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.93M
2
Bank of America
Bank of America
North Carolina
-$856K
3
AG
Artal Group
Luxembourg
-$722K
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$490K
5
FI
Fosun International
China
-$202K
Name Holding Trade Value Shares
Change 		Change in
Stake
AVAI
1
Atlas Venture Associates IX
Massachusetts
$15.8M – – –
ACM
2
Aquilo Capital Management
California
$13.3M +$1.2M +100,000 +9%
AI
3
Alphabet Inc
California
$12.8M – – –
BI
4
BVF Inc
California
$10.8M +$5.77M +478,998 +104%
BlackRock
5
BlackRock
New York
$7.56M +$2.84M +235,691 +56%
AIC
6
AWM Investment Company
New York
$6.89M +$434K +36,019 +6%
AG
7
Artal Group
Luxembourg
$6.21M -$722K -60,000 -10%
RSCM
8
Rock Springs Capital Management
Maryland
$6.04M – – –
O
9
OrbiMed
New York
$5.84M – – –
VMI
10
VHCP Management II
New York
$5.46M – – –
NHAS
11
Novo Holdings A/S
Denmark
$5.36M +$5.61M +465,983 New
Vanguard Group
12
Vanguard Group
Pennsylvania
$5.03M +$226K +18,814 +4%
Fidelity Investments
13
Fidelity Investments
Massachusetts
$2.63M -$1.93M -160,300 -41%
Renaissance Technologies
14
Renaissance Technologies
New York
$2.47M +$1.22M +101,600 +90%
State Street
15
State Street
Massachusetts
$1.95M +$727K +60,396 +55%
JP Morgan Chase
16
JP Morgan Chase
New York
$1.83M +$166K +13,814 +9%
GIM
17
Granahan Investment Management
Massachusetts
$1.59M -$26.9K -2,231 -2%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$1.32M +$245K +20,376 +22%
Dimensional Fund Advisors
19
Dimensional Fund Advisors
Texas
$1.22M +$1.07M +88,534 +495%
Northern Trust
20
Northern Trust
Illinois
$1.08M +$65.2K +5,416 +6%
FI
21
Fosun International
China
$962K -$202K -16,766 -16%
OAM
22
Oxford Asset Management
United Kingdom
$910K +$137K +11,377 +17%
DCM
23
DAFNA Capital Management
California
$806K – – –
BCM
24
Bridgeway Capital Management
Texas
$628K – – –
N
25
Nuveen
North Carolina
$431K +$451K +37,476 New
1
2 3

SPRO Hedge Fund Activity: Q2 2019 in Review

61 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Spero Therapeutics (SPRO) for Q2 2019, worth a combined $122M — up 3.2% from $119M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new SPRO positions and 3 closed out — a net gain of 6 holders — while 26 added to existing stakes and 10 trimmed.

The largest buyer was BVF Inc, adding an estimated $5.77M. The largest seller was Fidelity Investments, cutting an estimated $1.93M.

  • 61 institutional investors held Spero Therapeutics (SPRO) as of Q2 2019, up from 55 in Q1 2019.
  • Funds reported $122M of Spero Therapeutics stock for Q2 2019, up 3.2% quarter-over-quarter.
  • 9 funds opened new Spero Therapeutics positions in Q2 2019 and 3 closed out, a net change of +6 holders.
  • The largest Spero Therapeutics buyer in Q2 2019 was BVF Inc, an estimated $5.77M added.
  • The largest Spero Therapeutics seller in Q2 2019 was Fidelity Investments, an estimated $1.93M sold.

Based on aggregated 13F filings for Q2 2019.